5-[(Z)-(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-3-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 5-[(Z)-(3-carboxy-4-hydroxyphenyl)-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]-3-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid
• 化学式: C₃₀H₂₀O₁₂
• 分子量: 572.5
• InChiKey: DLAJVMQNALXDTI-MYYYXRDXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.03
• 拓扑面积：
  227
• 氢给体数：
  7
• 氢受体数：
  12

文献信息

• METHODS FOR DIAGNOSING AND TREATING CACHEXIA
  申请人：Aurin Biotech Inc.

  公开号：EP3630121A1

  公开（公告）日：2020-04-08
• [EN] METHODS FOR DIAGNOSING AND TREATING CACHEXIA<br/>[FR] MÉTHODES DE DIAGNOSTIC ET DE TRAITEMENT DE LA CACHEXIE
  申请人：AURIN BIOTECH INC

  公开号：WO2018218357A1

  公开（公告）日：2018-12-06

  A method of treating cachexia is provided. The method includes administering to a human in need thereof an effective amount of a complement inhibitor. The complement inhibitor may be a dimer of acetyl salicylic acid, including 5,5'-methylenebis(2-hydroxybenzoic acid), 4,4'-diacetoxy-1,1 biphenyl-3,3' dicarboxylic acid or a pharmaceutically acceptable salt thereof. The complement inhibitor may be aurin tricarboxylic acid, aurin quadracarboxylic acid, aurin pentacarboxylic acid, aurin hexacarboxylic acid, combinations thereof, and pharmaceutically acceptable salts thereof. The complement inhibitor may be an ester prodrug of the foregoing compounds.